deaths (OS)

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)

versus placebo
pembrolizumab alone vs. placebo 1 0.54 [0.30; 0.97], 1 RCT, I2=0%
unassessable degree of certainty